Peak Bio Statistics
Total Valuation
Peak Bio has a market cap or net worth of 520,310. The enterprise value is 9.33 million.
| Market Cap | 520,310 |
| Enterprise Value | 9.33M |
Important Dates
The last earnings date was Friday, November 22, 2024.
| Earnings Date | Nov 22, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Peak Bio has 23.12 million shares outstanding. The number of shares has increased by 18.70% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 23.12M |
| Shares Change (YoY) | +18.70% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 41.03% |
| Owned by Institutions (%) | 0.22% |
| Float | 10.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.92 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.81 |
| EV / Sales | 124.07 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.07
| Current Ratio | 0.07 |
| Quick Ratio | 0.04 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.43 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -247.74% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 12,532 |
| Profits Per Employee | -554,013 |
| Employee Count | 6 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -71.84% in the last 52 weeks. The beta is 1.60, so Peak Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.60 |
| 52-Week Price Change | -71.84% |
| 50-Day Moving Average | 0.08 |
| 200-Day Moving Average | 0.39 |
| Relative Strength Index (RSI) | 46.03 |
| Average Volume (20 Days) | 11,003 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Peak Bio had revenue of 75,192 and -3.32 million in losses. Loss per share was -0.14.
| Revenue | 75,192 |
| Gross Profit | -1.55M |
| Operating Income | -6.23M |
| Pretax Income | -3.32M |
| Net Income | -3.32M |
| EBITDA | -6.14M |
| EBIT | -6.23M |
| Loss Per Share | -0.14 |
Balance Sheet
The company has 862,144 in cash and 9.67 million in debt, giving a net cash position of -8.81 million or -0.38 per share.
| Cash & Cash Equivalents | 862,144 |
| Total Debt | 9.67M |
| Net Cash | -8.81M |
| Net Cash Per Share | -0.38 |
| Equity (Book Value) | -20.91M |
| Book Value Per Share | -0.90 |
| Working Capital | -20.86M |
Cash Flow
| Operating Cash Flow | -5.14M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -8,290.88% |
| Pretax Margin | -4,420.78% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Peak Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.70% |
| Shareholder Yield | -18.70% |
| Earnings Yield | -638.86% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |